Ranolazine for Prevention of Atrial Fibrillation after Cardiac Surgery: A Systematic Review

  • Patel N
  • Kluger J
N/ACitations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Postoperative atrial fibrillation (POAF) remains a major risk after cardiac surgery and is associated with an increased risk of stroke, length of stay, mortality, and cost. Ranolazine, an anti-anginal drug, also has anti-arrhythmic properties. The present study is to evaluate the effectiveness of ranolazine in preventing POAF after cardiac surgery. We searched the literature for clinical studies published up to August 2017 with a pre-defined inclusion and exclusion criteria. We identified four studies with a total of 754 patients of which 300 patients received ranolazine; there was a 14% decrease in POAF occurrence following cardiac surgery compared to 32% in the control group. Although ranolazine is an effective therapy in prevention of POAF, larger, multi-center, randomized trials are warranted.

Cite

CITATION STYLE

APA

Patel, N., & Kluger, J. (2018). Ranolazine for Prevention of Atrial Fibrillation after Cardiac Surgery: A Systematic Review. Cureus. https://doi.org/10.7759/cureus.2584

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free